Chair, Life Sciences Patent Practice
Robert is an intellectual property attorney focused on the life sciences industry. Over the course of his career, he has had the privilege of counseling clients on the discovery, design and protection of many successful therapeutic and diagnostic products with important commercial and humanitarian benefits.
Robert is a registered pharmacist and is able to speak the same language as the researchers, managers and investors with whom he interacts daily. He is particularly adept at analyzing complex issues and effectively communicating solutions that achieve his clients’ goals, whether it be raising capital, closing the deal or obtaining a bet-the-company patent. As a testament to his reputation and recognition in the field, Robert has served as an Adjunct Professor at Rutgers University Law School for the past five years, where he teaches patent drafting and prosecution.
Robert is the Chair of the Life Sciences Patent practice at Lowenstein Sandler and has significant experience in virtually all aspects of intellectual property, including patent prosecution, noninfringement, patentability, litigation, freedom to operate and technology transfer. He also regularly advises clients on product acquisition and divestiture, joint ventures and alliances, technology licensing, outsourcing, and other technology-related transactions.
|
Obtained a groundbreaking patent that is listed in the FDA Orange Book for a tamper resistant formulation of an FDA-approved narcotic analgesic.
|
|
Obtained Orange Book listed patents for a specialty pharmaceutical company specializing in acute hospital care. The patents encompass four currently marketed formulations of an injectable antihypertensive product and were the driving force for the eventual acquisition of the company.
|
|
Obtained multiple patents covering a Phase III injectable product for the treatment of adverse effects of chemotherapy.
|
|
Robert J. Paradiso spotlighted as a contributor for his insights on intellectual property rights and claims that have arisen as a result of the human genome project.,
RegentAtlantic Capital, LLC
,
December 2007
|
|
Robert J. Paradiso comments on the Patent Reform Act of 2007 and key concerns among biotechnology companies.,
NJBiz
,
September 13, 2007
|